CD274 and acute myeloid leukemia: A randomized phase 2 trial of AZA with or without durvalumab (DURV), a PD-L1 inhibitor, as first-line treatment for elderly AML patients failed to show a potential benefit; the addition of DURV did not enhance clinical outcomes, and recorded ORR and OS were similar among both treatment arms [99].